Paige Holden, Lakshmi R Nair
Dec 1, 2019
Citations
3
Influential Citations
56
Citations
Journal
Tissue engineering. Part B, Reviews
Abstract
Deferoxamine (DFO) has been in use for half a century as an FDA approved iron chelator, but recent studies indicate a variety of properties that could expand this drug's application into the fields of tissue and regenerative engineering. DFO has been implicated as an angiogenic agent in studies on ischemia, wound healing, and bone regeneration due to its ability to upregulate HIF-1α and other key downstream angiogenic factors. DFO has also demonstrated antioxidant capabilities unrelated to its iron chelating properties, making it a potential modulator of the oxidative stress involved in the inflammation response. Together, these properties make DFO a potential bioactive molecule to promote wound healing and enhance tissue integration of biomaterials in vivo.